Myozyme / Lumizyme

At a Glance
Therapeutic Area:
Enzyme Replacement Therapy
Approved Applications:
Myozyme®/Lumizyme (alglucosidase alfa) is a lysosomal glycogen-specific enzyme indicated for use in patients with Pompe disease (GAA deficiency). Pompe disease is a rare, progressive and often fatal neuromuscular disease. Myozyme replaces or supplements this enzyme in patients in whom is it is deficient.
Applications In Development:
Acquisition Date:
January 2011
Royalty Seller:


Latest News

  • No results
© 2014 Royalty Pharma, RP Management LLC. All Rights Reserved.